Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

R.L. Coleman, A.M. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J.I. Weberpals, A. Clamp, G. Scambia, A. Leary, R.W. Holloway, M.A. Gancedo, P.C. Fong, J.C. Goh, D.M. O'Malley, D.K. Armstrong, J. Garcia-Donas, E.M. Swisher, A. FloquetG.E. Konecny, I.A. McNeish, C.L. Scott, T. Cameron, L. Maloney, J. Isaacson, S. Goble, C. Grace, T.C. Harding, M. Raponi, J. Sun, K.K. Lin, H. Giordano, J.A. Ledermann

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1949-1961
Number of pages13
JournalThe Lancet
Issue number10106
Publication statusPublished - 2017

Cite this